Benaroya Research Institute (BRI) is a world leader in human immune system research. BRI works to advance the science that will predict, prevent, reverse and cure immune system diseases like allergies, asthma, cancer, COVID-19 and autoimmune diseases. BRI accelerates discovery through laboratory breakthroughs in immunology that are then translated to clinical therapies. We believe that a breakthrough in one immune system disease can lead to progress against them all, and work tirelessly toward our vision of a healthy immune system for everyone. BRI is a world-renowned independent nonprofit research institute affiliated with Virginia Mason Franciscan Health and based in Seattle.
Benaroya Research Institute Welcomes Three New Board Members
Benaroya Research Institute at Virginia Mason (BRI) announced three new members to its Board of Directors: Nabil Istafanous, Ben Reiber and Catherine Zimmerman.
Nabil Istafanous, JD, is Principal, Corporate Counsel Solutions PLLC and an experienced governance, compliance and ethics consultant and healthcare attorney. Previously he has served as the Chief Compliance and Ethics officer for Group Health and Premera Blue Cross.
Ben Reiber, MBA, CFA, is Vice President, Investment Management Division, Goldman, Sachs & Co. where he is focused on investment management, strategic and tactical asset allocation and financial risk management for individuals, foundations and companies.
Catherine Zimmerman is a human resources professional, previously employed by Merck & Co., currently serving as a mediator and conflict resolution coach. She has served on the AJC Seattle Regional Board and received a Bronze Presidential Volunteer Service Award for mediation from the City of Bellevue.
“We’re grateful to these individuals for volunteering their valuable time and support,” said Gerald Nepom, MD, PhD, director of BRI, “I’m certain that along with our other distinguished board members, their guidance will continue to ensure BRI’s leadership in scientific innovation and medical advancements.”